In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vifor Fresenius Medical Care Renal Pharma Ltd.

Division of Vifor Pharma Group

Latest From Vifor Fresenius Medical Care Renal Pharma Ltd.

Cara’s Phase III Success In CKD-Pruritus Puts NDA Filing In Sight

Second Phase III study expected later this year, but Cara wants to discuss the possibility of accelerated filing with the US FDA. It also has an oral formulation in Phase II for less severe CKD patients.

Clinical Trials Drug Approval Standards

ChemoCentryx/Vifor Change Tack On EU Avacopan Filing

ChemoCentryx and Vifor Fresenius have changed their conditional marketing authorization application for avacopan to a full MAA in the EU after it emerged that data from the ADVOCATE study will be more comprehensive than expected.
Approvals Europe

Cara Therapeutics' Stock Buoyed By Positive Korsuva Data For Post-Op Pain

Cara Therapeutics will discuss its options with regulators after positive top-line data from adaptive Phase II/III trial of its Korsuva drug in patients undergoing abdominal surgeries met its prime endpoint and sent the biotech's stock higher.

Clinical Trials Companies

Deal Watch: Allergan, Celgene, AstraZeneca Among Biopharmas Advancing Existing Partnerships

Recent deal-making has seen new developments to further existing agreements, including Allergan licensing a depression candidate from the spinout of a company it bought in 2015. Also, updates on deals involving Celgene, AstraZeneca and Daiichi Sankyo.

Deals Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Renal System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Vifor Pharma Group
  • Senior Management
  • Stefan Schulze, CEO
  • Contact Info
  • Vifor Fresenius Medical Care Renal Pharma Ltd.
    Phone: 58 851 80 00
    Flughofstrasse 61
    Glattbrugg, CH-8152
    Switzerland
Advertisement
Advertisement
UsernamePublicRestriction

Register